Assertio Holdings WKN: A3CRAA ISIN: US04546C2052 Forum: Aktien User: Summer.76

Na nun ja nicht mehr 😉 Ja, sie war jetzt bemüht 🙃📈 Es gibt hierzu noch ein weiteres Forum. Möglicherweise liegt es daran.

Assertio Holdings: Recent Breakout To Lead To Sustained Gains https://seekingalpha.com/article/4500271-assertio-holdings-recent-breakout-leading-to-sustained-gains Summary • Company grows the top-line by 7% in Q4 due to strong performances from Indocin, Cambia & Zipsor. • Promising guidance eventually led to a breakout above the January highs. • We look at Assertio's profitability and valuation metrics to see if the breakout has merit. ...

Assertio Reports First Quarter 2022 Financial Results https://www.globenewswire.com/news-release/2022/05/09/2439008/0/en/Assertio-Reports-First-Quarter-2022-Financial-Results.html Reaffirms Full Year Net Product Sales and Raises Full Year Non-GAAP Adjusted EBITDA Guidance Net Product Sales Up 37% and Non-GAAP Adjusted EBITDA Up 52% Compared to Prior Year Quarter Quarterly Net Cash Flows from Operating Activities of $27.4 Million

Assertio Therapeutics Non-GAAP EPS of $0.38, revenue of $36.54M beats by $3.48M https://seekingalpha.com/news/3835430-assertio-therapeutics-non-gaap-eps-of-0_38-revenue-of-36_54m-beats-3_48m • Assertio Therapeutics press release (NASDAQ:ASRT): Q1 Non-GAAP EPS of $0.38. • Revenue of $36.54M (+36.1% Y/Y) beats by $3.48M. • 2022 Financial Guidance • Net Product Sales (GAAP): $126.0 Million to $136.0 Million • Adjusted EBITDA (Non-GAAP): $66.0 Million to $74.0 Million

Assertio Holdings: Management Still Swimming Against The Tide https://seekingalpha.com/article/4517731-assertio-holdings-management-still-swimming-against-the-tide Summary • In a note 12 months ago I told the story of how Assertio, formerly DepoMed, nearly went under after its disastrous acquisition of opioid drug Nucynta. • A new management team was able to dispose of the asset, settle debts, and acquire a portfolio of NSAIDs, which have driven exceptional cash flow. • The forecast for 2022 is for $126-136m of revenues and EBITDA of $64-72m. • That's remarkable, but it may obscure the fact that sales volumes of lead asset Indocin appear to be shrinking and there's limited scope for new product acquisitions. • It's a tough ask for management to keep Assertio afloat in a sea of troubles caused by opioid exposure and litigation. Approach with caution. ...

Assertio Holdings, Inc. Partners with BlinkRx to Support Healthcare Providers and Patients Utilizing Otrexup® (methotrexate) with a Unique Patient Access Solution Collaboration Eases Patient Access to Therapy https://www.globenewswire.com/news-release/2022/03/31/2413910/0/en/Assertio-Holdings-Inc-Partners-with-BlinkRx-to-Support-Healthcare-Providers-and-Patients-Utilizing-Otrexup-methotrexate-with-a-Unique-Patient-Access-Solution.html

Assertio Reports Fourth Quarter and Full Year 2021 Financial Results https://www.globenewswire.com/news-release/2022/03/09/2399962/0/en/Assertio-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results.html $32.2 Million Fourth Quarter Net Product Sales, a 7% Increase from Fourth Quarter 2020 and $109.4 Million Full Year Net Product Sales $17.8 Million Fourth Quarter Non-GAAP Adjusted EBITDA, a 118% Increase from Fourth Quarter 2020 and $48.8 Million Full Year Non-GAAP Adjusted EBITDA Provides 2022 Net Product Sales Guidance Range of $126.0 Million to $136.0 Million and 2022 Non-GAAP Adjusted EBITDA Guidance Range of $64.0 Million to $72.0 Million Completed Acquisition of Otrexup® (methotrexate)